ENVB — Enveric Biosciences Share News
0.000.00%
Last trade - 00:00Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
Enveric Biosciences Q1 net loss narrows as funding rises
Brief: Enveric Biosciences Inc - Reports Positive Preclinical Results For Eb-003 In Ptsd Model
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
NASDAQ RESUMED AT 10:58 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:53 AM
NASDAQ RESUMED AT 10:03 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:48 AM
Compass Pathways rises after FDA fast-tracks psychedelic drug research
Psychedelic drug developers rise after Trump signals regulatory support
Psychedelic drug developers rally as Trump orders FDA to expedite reviews (updated)
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Psychedelic drug developers rise after Trump signals regulatory support
Brief: Enveric Biosciences Announces Closing Of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules